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A B S T R A C T
Purpose
The use of multiple and/or inappropriate medications in seniors is a significant public health
problem, and cancer treatment escalates its prevalence and complexity. Existing studies are
limited by patient self-report and medical record extraction compared with a pharmacist-led
comprehensive medication assessment.
Patients and Methods
We retrospectively examined medication use in ambulatory senior adults with cancer to determine
the prevalence of polypharmacy (PP) and potentially inappropriate medication (PIM) use and
associated factors. PP was defined as concurrent use of five or more and less than 10
medications, and excessive polypharmacy (EPP) was defined as 10 or more medications. PIMs
were categorized by 2012 Beers Criteria, Screening Tool of Older Person’s Prescriptions (STOPP),
and the Healthcare Effectiveness Data and Information Set (HEDIS).
Results
A total of 248 patients received a geriatric oncology assessment between January 2011 and June
2013 (mean age was 79.9 years, 64% were women, 74% were white, and 87% had solid tumors).
Only 234 patients (evaluated by pharmacists) were included in the final analysis. Mean number of
medications used was 9.23. The prevalence of PP, EPP, and PIM use was 41% (n  96), 43% (n
 101), and 51% (n  119), respectively. 2012 Beers, STOPP, and HEDIS criteria classified 173
occurrences of PIMs, which were present in 40%, 38%, and 21% of patients, respectively.
Associations with PIM use were PP (P  .001) and increased comorbidities (P  .005).
Conclusion
A pharmacist-led comprehensive medication assessment demonstrated a high prevalence of PP,
EPP, and PIM use. Medication assessments that integrate both 2012 Beers and STOPP criteria
and consider cancer diagnosis, prognosis, and cancer-related therapy are needed to optimize
medication use in this population.
J Clin Oncol 33:1453-1459. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The American Cancer Society estimates that by the
year 2030, 70% of all cancers in United States will be
diagnosed in senior adults.1 The multiple layers of
specialists (ie, oncologists, radiation oncologists,
surgeons, geriatricians), primary care, and allied
health professionals in the continuum of care makes
this population a challenge to manage. Older adults
with cancer are particularly prone to medication
errors attributed to medication changes, complex
regimens, and incomplete information handoff be-
tween providers.2,3 Polypharmacy (PP) and poten-
tially inappropriate medication (PIM) use warrant
substantial interest and concern on behalf of medi-
cal oncologists and oncology health providers be-
cause of the perils associated with their use in this
vulnerable population; vulnerabilities include in-
creased risk of falls and/or fractures, cognitive im-
pairment, and delirium, all of which can lead to
compromised cancer management plans (eg,
treatment delays and/or premature treatment dis-
continuation). Cancer-related therapy adds to the
prevalence of the use of multiple medications and/or
the consumption of inappropriate medications be-
cause new medications escalate their prevalence and
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complexity, which consequently increases the risk for adverse drug
effects, drug-drug interactions, and nonadherence as a result of
increased pill burden and regimen complexity.4-8 Increased pill
burden increases the risk of drug-drug, drug-food, and drug-
herbal interactions, and medical oncologists may not know how to
manage such issues.
A comprehensive medication review is considered to be an inte-
gral part of the geriatric oncology assessment.9,10 Extermann et al9 and
the National Comprehensive Cancer Network Older Adult Oncology
Guidelines10 both recommend a comprehensive medication assess-
ment, which includes a thorough a review of patients’ medications
with subsequent discontinuation of any nonessential medications and
evaluation for drug interactions, adverse effects, and patient adher-
ence; however, such guidelines do not state which health care profes-
sional should be performing the medication assessment. Existing
studies that report on the prevalence of PP and PIM use, specifically in
ambulatory senior adults with cancer, report the prevalence of PP as
48% to 80% and PIM use as 8% to 41%. These studies are scarce and
are limited by antiquated criteria and/or screening tools for defining
PP and PIM use, and excessive polypharmacy (EPP) has never been
examined.11-14 In addition, the methodologies used in previous stud-
ies were flawed by the inherent pitfalls in measuring medication use by
using patient self-reports and medical records extraction compared
with using a pharmacist-led comprehensive medication assessment,
which should be recognized as a best practice benchmark. On that
basis, we designed this study to examine the prevalence of PP, EPP,
and PIM use and factors influencing their use on the basis of a
pharmacist-led comprehensive medication assessment in ambulatory
senior adults with cancer at our institution.
PATIENTS AND METHODS
This protocol was approved by the institutional review board at our institution
before initiation. This was a retrospective study (data were collected from
physicians’ and clinical pharmacists’ electronic progress notes documented in
the electronic medical record). All patients who received an initial geriatric
oncology assessment at our senior adult oncology ambulatory center between
January 2011 and June 2013 and had a diagnosis of cancer (all cancer types and
all cancer stages) were included in the study. Our center is an outpatient
ambulatory center that provides half-day services (5 hours) twice per week at
two sites within the health care system. The core Older Adult Oncology
Table 1. Patient Demographic and Clinical Characteristics
Characteristic No. %
Age, years
Mean 79.91
SD 6.84
Range 61-98
Age range, years
60-69 16 6
70-79 91 37
80-89 122 49
90-99 19 8
Sex
Female 159 64
Male 89 36
Race/ethnicity
White 184 74.2
African American 48 19.4
Asian 9 3.6
Hispanic 6 2.4
Other 1 0.4
Cancer type
Solid malignancies
Colorectal 46 19
Breast 45 18
Lung 39 16
Urinary tract (bladder, renal, urethral, urothelial) 18 7.3
Upper GI (pancreatic, bile duct, gall bladder) 15 6
Esophageal 9 3.6
Neuroendocrine 8 3.2
Gastric 7 2.8
Prostate 7 2.8
Sarcoma 6 2.4
Head and neck 5 2
Gynecologic 5 2
Duodenal 2 0.8
Melanoma/skin cancer 2 0.8
Unknown primary 2 0.8
Mesothelioma 1 0.4
Hematologic malignancies
Lymphoma 13 5.2
Myeloma 8 3.2
Leukemia 5 2
Myelodysplastic syndrome 2 0.8
Other
Polycythemia vera 2 0.8
Amyloidosis 1 0.4
Waldenström macroglobulinemia 1 0.4
Cancer stage
0 4 1.6
I 31 12.5
II 59 23.8
III 46 18.6
IV 65 2.6
Unknown 1 0.4
Recurrence
Local 5 2
Metastatic 29 11.7
Staging not applicable 8 3.2
Functionality status†
Fit 57 23.3
Vulnerable 120 49
Frail 68 27.8
(continued in next column)
Table 1. Patient Demographic and Clinical Characteristics (continued)
Characteristic No. %
Comorbidity count
Mean 7.69
SD 3.47
ECOG performance score (n  247)
0 71 29
1 108 44
2 58 23
3 9 4
4 1 0.4
Abbreviations: ECOG, Eastern Cooperative Oncology Group; SD, stan-
dard deviation.
Dual primary (lung and head and neck) malignancy.
†Functionality status (n  245).
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multidisciplinary team consisted of a medical oncologist, geriatrician, patient
navigator, clinical pharmacist, social worker, and a registered dietician.
As a standard of care at our center, patients were instructed to bring in all
medications (prescription, nonprescription, herbals, and supplements) for the
pharmacist-patient session. During the session, the pharmacist evaluated each
medication with the patient and/or caregiver to confirm medication posses-
sion and/or self-administration, indication, and adverse effects; in addition,
the pharmacist assessed the patient’s ability to read medication label directions
and to manage medications in an organized manner. The pharmacist provided
medication-related education, addressed medication-related problems with
the patient and the interdisciplinary health care team, updated the medication
record, and documented a progress note in the electronic medical record. The
pharmacist’s medication-related recommendations (eg, discontinuation of
unnecessary and/or inappropriate medications, recommendation of alterna-
tives) were part of the comprehensive assessment and were forwarded to the
primary oncologist and/or medical provider for evaluation and follow-up. PP
was defined as concurrent use of five or more and less than 10 medications, and
EPP was defined as concurrent use of 10 or more medications, including
prescription, nonprescription, herbal, and supplement medications.15-18
PIM use was categorized on the basis of three screening tools, including
the 2012 Beers criteria, the Screening Tool of Older Person’s Prescriptions
(STOPP) criteria, and the Healthcare Effectiveness Data and Information Set
(HEDIS) criteria for drugs to avoid in the elderly.19-23 These three screening
tools were used in this study because they represent the most current,
evidence-based, clinically validated criteria in the literature. There is no
head-to-head trial that recommends the use of one screening tool over
another, so each of these tools is considered a viable option for use in
clinical practice. The 2012 Beers criteria is the screening tool used in
clinical practice in the United States and is supported and endorsed by the
American Geriatrics Society. The STOPP criteria is a European screening
tool developed on the basis of expert consensus and evidence-based crite-
ria, and it incorporates commonly encountered instances of potentially
inappropriate prescribing in senior adults, and it includes drug-drug and
drug-disease interactions, drugs that adversely affect seniors at risk of falls,
and duplicate drug class prescriptions. HEDIS is a health care quality
measure used in the United States that was created by the National Com-
mittee on Quality Assurance to examine the quality of prescribing for older
patients. The American Geriatrics Society stated that the STOPP criteria
should be used in a complementary manner with 2012 Beers criteria to
guide clinicians in making decisions about safe medication use in senior
adults, largely because there are some notable differences between these
screening tools.
Demographic and clinical patient information was collected from med-
ical records and included age, sex, race, cancer type and cancer stage, comor-
bidities (number and type), and Eastern Cooperative Oncology Group
(ECOG) performance status24 and functional status by using stages of aging
described as fit, vulnerable, or frail as determined by the geriatrician. Balducci
et al25 defined “fit” patients as those who lacked serious comorbidity and were
functionally independent without evidence of geriatric syndromes. “Vulnera-
ble” patients were dependent in one or more instrumental activities of daily
living and had several more significant comorbid conditions. “Frail” patients
were dependent in activities of daily living, had evidence of geriatric syn-
dromes, and had significant comorbidities. PP and PIM factors that influenced
or were associated with age, sex, PP, comorbidities, ECOG performance status,
and functional status were analyzed. Descriptive statistics were calculated by
using Fisher’s exact test, Pearson’s 2 test for categorical variables, Wilcoxon’s
test for continuous variables, and the Kruskal-Wallis test for assessments
between groups.
RESULTS
Data were collected from 248 consecutive patients who received an
initial geriatric oncology assessment at our institution between Janu-
ary 2011 and June 2013. The mean age was 80 years, 159 patients
(64%) were women, and the mean number of comorbidities was 7.69
(excluding primary cancer). Two hundred sixteen patients (87%) had
solid tumors, and 32 patients (13%) had hematologic malignancies. A
majority with solid tumors had advanced-stage or metastatic disease.
Table 1 displays the distribution of patients’ baseline characteristics
and Table 2 identifies patient characteristics by comorbidity type. Of
the 248 patients evaluated at our center, 234 (94%) were seen by a
clinical pharmacist for a comprehensive medication assessment and
were included in the final analysis (the remaining 14 patients were
evaluated on days on which pharmacist coverage was not readily
available). Evaluation of the 234 patients by a clinical pharmacist
Table 2. Prevalence of Comorbidities by Disease Status (n  248)
Comorbidity No. %
Cardiovascular 230 92.7
Hypertension 187 75.4
Dyslipidemia 147 59.3
Arrhythmias 58 23.4
Congestive heart failure 51 20.6
Coronary artery disease 43 17.3
Stroke 40 16.1
Venous thromboembolism 26 10.5
Ischemic heart disease 12 4.8
Endocrine 117 47.2
Diabetes 77 31.1
Thyroid disease 62 25
Respiratory 88 35.5
Chronic obstructive pulmonary disease 56 22.6
Asthma 18 7.3
GI 108 43.6
Gastroesophageal reflux 68 27.4
Constipation/diarrhea 36 14.5
Peptic ulcer 21 8.5
Irritable bowel syndrome 12 4.8
Renal 43 17.3
Chronic kidney disease 33 13.3
Electrolyte disorders 4 1.6
Neurologic 89 35.9
Pain management 63 25.4
Alzheimer’s disease 25 10.1
Epilepsy 5 2
Headache 4 1.6
Psychiatric 91 36.7
Anxiety 58 23.4
Depression 54 21.8
Sleep disorder 15 6.1
Schizophrenia 4 1.6
Urologic 68 27.42
Benign prostatic hypertrophy 32 12.9
Urinary incontinence 42 16.94
Rheumatologic 162 65.32
Osteoarthritis 127 51.2
Osteoporosis 61 24.6
Gout 15 6.1
Rheumatoid arthritis 4 1.6
Ophthalmic 68 27.4
Cataract 68 27.4
Glaucoma 28 11.3
Macular degeneration 13 5.2
Hematologic 82 33.1
Anemia 82 33.1
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showed that they took 2,163 total medications, 1,430 prescription
medications, 647 nonprescription medications, and 86 herbal
medications. The mean number of medications used by patients
was 9.23 (standard deviation [SD], 4.79; range, 1 to 30 medica-
tions). The medications were as follows: 6.1 prescription medica-
tions (SD, 3.58; range, 0 to 20 prescription medications), 2.76
nonprescription medications (SD, 2.11; range, 0 to 10 nonpre-
scription medications), and 0.38 herbal medications (SD, 0.88;
range, 0 to 10 herbal medications;). The prevalence of PP, EPP, and
PIM use was 41%, 43%, and 51%, respectively. Table 3 shows that
the most common prescription medications were drugs that act on
the cardiovascular system at a prevalence of 77%, dyslipidemics at
53%, GI medications at 41%, diuretic medications at 40%, and
endocrine-related medications at 37%. Appendix Table A1 (online
only) lists comorbidity types associated with PP category.
2012 Beers, STOPP, and HEDIS criteria classified 173 occur-
rences of PIMs present in 40% (n 94), 38% (n 88), and 21% (n
49) of patients, respectively. BEERs and STOPP criteria were most
inclusive, each detecting 118 occurrences, and HEDIS detected 58
occurrences (of 173 occurrences). Mutual overlap between Beers and
STOPP criteria occurred in 38% of PIM use (66 of 173 occurrences).
The mean number of inappropriate medications used by patients was
0.74 (SD, 0.89; range, 0 to 4 inappropriate medications). The propor-
tion of study participants who were prescribed 0, 1, 2, 3, and 4 PIMs
was 49%, 34%, 12%, 4%, and 1%, respectively. The most prevalent
PIMs are listed in Table 4 and include benzodiazepines (16%), GI
medications (9.4%), nonsteroidal anti-inflammatory drugs (8.5%),
antiplatelet medications (8%), and first-generation antihistamines
(6%). The most common medications detected by 2012 Beers (but not
by STOPP) criteria were short- and intermediate-acting benzodiaz-
epines and sedative hypnotics. The most common medications de-
tected by STOPP (but not by 2012 Beers) criteria were antiplatelet
medications (specifically, aspirin at doses above 150 mg per day),
beta-blockers (noncardioselective beta-blocker with chronic obstruc-
tive pulmonary disease), and proton pump inhibitors (for peptic
ulcers at the full therapeutic dose for more than 8 weeks). In Table 5,
patient characteristics associated with PP were increased number of
comorbidities, increased PIM use, reduced ECOG performance status
at baseline, and reduced functional status at baseline. Patient charac-
teristics associated with PIM use (v no PIMs) were PP (P  .001)
and increased number of comorbidities (P  .005), as listed in
Table 6. Specific comorbidities that were associated with PIM use
were cardiovascular (P  .014), GI (P  .013), neurologic (P 
.020), and psychiatric (P  .001) conditions, as summarized in
Appendix Table A2 (online only). The rate of PIM use differs
between PP categories, as illustrated in Appendix Figure A1 (online
only). The mean number of PIMs used between no PP, PP, and
EPP is 0.19, 0.6, and 1.07, respectively. The PIM use rate between
no PP and PP is 6% versus 9% (P .001).
DISCUSSION
In this cohort of senior adult oncology patients, a pharmacist-led
medication assessment identified a high prevalence of PP, EPP, and
PIM use compared with previously reported methodologies. Studies
reporting on the prevalence of PP and PIM use, specifically in ambu-
latory older adults with cancer, are limited. Lichtman et al11 published
an abstract on PIM use in older patients with cancer in the outpatient
setting. The investigation identified PIM use in 11% of patients on the
Table 3. Prevalence of Prescription Medications by Pharmacologic Category (n  234)
Pharmacologic Category Prescription Medication No. %
Cardiovascular Alpha-adrenergic agonists/antagonists, antiarrhythmics, beta-adrenergic antagonist, calcium channel
antagonists, digoxin, renin-angiotensin aldosterone antagonists, vasodilators
180 76.9
Dislipidemics Statins, ezetimibe, niacin, fenofibrate, colesevelam 124 53
GI Antiemetics, antispasmodics, constipation/diarrhea, histamine-2 antagonist, protectants, irritable
bowel syndrome, proton pump inhibitors
96 41
Diuretic 94 40.2
Endocrine Antidiabetic oral/injectable, thyroid replacement, antithyroid agents 87 37.2
Analgesic Nonsteroidal anti-inflammatory drugs, opioids/nonopioids, neuropathic pain drugs, topical anesthetics 69 29.5
Antiplatelet/anticoagulant 53 22.7
Neuropsychiatric Antidepressants, anti-Parkinson agents, antipsychotics, anticonvulsants 51 21.8
Vitamin/minerals 45 19.2
Pulmonary/respiratory Inhalers, oral tablets 44 18.8
Genitourinary 40 17.1
Benzodiazepine/barbiturate 39 16.7
Ophthalmic 31 13.2
Antimicrobial Antibacterials, antifungals, antivirals 22 9.4
Bone health Bishphosphonates (oral), parathyroid hormone analog, calcium, vitamin D agent 20 8.6
Glucocorticoid 17 7.3
Gout 11 4.7
Sedative hypnotic 10 4.3
Hormonal Hormonal estrogens, androgens 8 3.4
Dermatologic topicals 5 2.1
Anti-neoplastic Oral antineoplastics including conventional, targeted agents 4 1.7
Central nervous system stimulant 1 0.4
Otic 1 0.4
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basis of 2003 Beers criteria, and the median number of medications
used was 8 (range, 0 to 23 medications). Maggiore et al12 published an
abstract on PP, PIM use, and chemotherapy-related adverse events
among older adults with cancer. That study evaluated 500 patients
with a mean age of 73 years, and the mean number of daily medica-
tions used was five. The prevalence of PP was 48% (239 of 500), and
the prevalence of PIM use ranged from 11% (53 of 500) to 18% (89 of
500), depending on the tool used to classify PIM use (2003 Beers criteria
Table 4. Prevalence of PIMs by Pharmacologic Category (n  234)
Pharmacologic Category PIMs No. %
Benzodiazepine 38 16.2
GI Antiemetics, anticholinergic/antispasmodics, constipation/diarrhea, proton pump inhibitors 22 9.4
Nonsteroidal anti-inflammatory drugs 20 8.6
Antiplatelet 19 8.1
Antihistamine 14 6
Beta-adrenergic antagonist 13 5.6
Sedative hypnotic 7 3
Neuropsychiatric Antipsychotics 6 2.6
Cardiovascular Antiarrhythmics, calcium channel antagonists 6 2.6
Endocrine Long-acting sulfonylureas, sliding-scale insulin, dessicated thyroid 6 2.6
Diuretic Hydrochlorothiazide 4 1.7
Hormonal Conjugated estrogens, megesterol 4 1.7
Muscle relaxant 2 0.9
Antibiotic Nitrofurantoin 1 0.4
Anticholinergic Benztropine 1 0.4
CNS stimulant 1 0.4
Genitourinary Oxybutinin 1 0.4
Abbreviation: PIM, potentially inappropriate medication.
Table 5. Patient Characteristics Associated With PP (n  234)
Characteristic
No PP ( 5
medications)
(n  37)
Any PP ( 5
medications)
(n  197)
P
PP ( 5 and
 10
medications)
(n  96)
EPP ( 10
medications)
(n  101)
PNo. % No. % No. % No. %
Age, years .491 .397
Mean 79.03 79.93 80.34 79.53
SD 7.4 6.65 7.32 5.95
Sex .265 .986
Female 27 72.97 123 62.44 60 62.5 63 62.38
Male 10 27.03 74 37.56 36 37.5 38 37.62
Race/ethnicity .861 .109
White 25 67.57 148 75.13 67 69.79 81 80.2
African American 9 24.32 36 18.27 18 18.75 18 17.82
Asian 2 5.41 7 3.55 6 6.25 1 0.99
Hispanic 1 2.70 5 2.54 4 4.17 1 0.99
Other 0 0.00 1 0.51 1 1.04 0 0
Functional status (n  232)  .001  .001
Fit 21 58.33 33 16.84 25 26.32 8 7.92
Frail 3 8.33 60 30.61 22 23.16 38 37.62
Vulnerable 12 33.33 103 52.55 48 50.53 55 54.46
No. of comorbidities  .001  .001
Mean 4.59 8.60 7.21 9.93
SD 2.19 3.40 2.86 3.36
Median 5 8 6 6
Range 1-10 2-21 2-15 3-21
PIM use 7 18.92 112 56.85  .001 42 43.75 70 69.31  .001
ECOG performance status (n  233) .005 .048
0-1 34 91.89 136 69.39 73 76.04 63 63
2-4 3 8.11 60 30.61 23 23.96 37 37
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EPP, excessive polypharmacy; PIM, potentially inappropriate medication; PP, polypharmacy; SD,
standard deviation.
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or 2001 Zhan criteria). In 2013, Maggiore et al14 published a modified
abstract on PIM use and chemotherapy-related adverse events using the
2012 Beers criteria. The prevalence of PIM use ranged from 11% to 29%,
dependingonthetoolusedtoclassifyPIMuse(2001Zhancriteriaor2012
Beerscriteria).Prithvirajetal13 evaluatedpatientcharacteristicsassociated
withPPandinappropriateprescribingofmedicationsamongolderadults
with cancer, which included 117 patients with a mean age of 74.6 years.
The mean number of daily medications was 7.3, the prevalence of PP was
80%,andtheprevalenceofPIMusewas41%(2003Beerscriteria).Finally,
a study by Sokol et al26 retrospectively evaluated medication use in
senior adults with cancer (mean age, 79 years) at a large commu-
nity oncology facility in an academic practice setting. Sokol et al
identified a mean number of 9.1 medications used by patients in
their cohort; however, the majority of patients were receiving
concurrent chemotherapeutic agents. PIM use was not reported.
Our study shows a mean number of 9.2 medications used by the
cohort, 41% prevalence of PP, and 43% prevalence of EPP, which is
slightly higher than in previous publications. The reduced prevalence
of PP reported by previous publications may be associated with the
fact that previous investigations were based on antiquated criteria
and/or screening tools for defining PP and PIM use in the elderly, and
EPP was not defined or examined in any of these studies. The majority
of these investigations assessed medications and medication use on the
basis of usual care standards, defined as physician- or prescriber-
directed medication assessments documented in medical records
and/or medication databases compared with a pharmacist-directed
comprehensive medication assessment, which may explain a higher
prevalence of PP in our study compared with that in previous publi-
cations. Similarities between 2012 Beers and STOPP criteria include
nonsteroidal anti-inflammatory drugs, tricyclic antidepressant medi-
cations, and long-acting benzodiazepine medications. Differences in-
clude items in the STOPP criteria such as the use of noncardioselective
beta blockers in chronic obstructive pulmonary disease, the use of
aspirin at dosages greater than 150 mg per day, and the use of proton
pump inhibitors for treatment durations of greater than 8 weeks,
which are not included in 2012 Beers criteria. The American Geriatrics
Society highlights the notion that the STOPP criteria be used in a
complementary manner with 2012 Beers criteria to guide clinicians in
making decisions about safe medication use in senior adults. This
recommendation is accurate and is reinforced by the fact that in our
study, there was insufficient overlap between the 2012 Beers and
STOPP criteria, because both tools combined mutually identified 66
(38%) occurrences of PIM use, further supporting the fact that use of
both tools may be seen as complementary.
In this study, patient characteristics associated with PP (v no PP)
were increased number of comorbidities (P .001), increased PIM use
(P .001),reducedECOGperformancestatusatbaseline(P .005),and
reduced functional status at baseline (P .001). Prithviraj et al13 found
that patients who were taking five or more medications (compared with
5 concurrent medications) were statistically significantly more likely to
have poor functional status, have five or more comorbidities, and be
prescribed a PIM per 2012 Beers criteria. The authors found an associa-
tion between medication use and ECOG performance scores, with pa-
tients taking multiple medications more likely to have poorer
performance status, which was also found in our study. Finally, our study
found associations between PIM use (v no PIM use) and PP (P .001)
andincreasednumberofcomorbidities(P .005), specificallycardiovas-
cular, GI, neurologic, and psychiatric conditions.
To the best of our knowledge, our study is the first of its kind
to incorporate a pharmacist-led comprehensive medication assess-
ment using the most current, evidence-based, clinically validated
criteria and screening tools to examine the prevalence of PP, EP,
and PIM use in this complex population. Studies show that when
pharmacists are involved in care transitions and take measures
to decrease the prevalence of multiple medication use and
medication-related problems, hospital readmission rates and pre-
ventable adverse drug events are reduced; however, these studies
are mostly limited to the inpatient setting in the area of medication
reconciliation and discharge programs.3,27-33 Although these inpa-
tient programs provide a robust framework, identifiable gaps exist
because the literature does not focus on the ambulatory care setting
or the oncology population. Integrating clinical pharmacy services
in this multidisciplinary team may have the potential to optimize
patient medication use and health outcomes by providing compre-
hensive medication assessment and planning (for both oncology
and medicine issues), all before initiating cancer and/or supportive
care treatment.
This study has some shortcomings that limit its clinical applica-
bility to the larger population. This was a single-institution study with
a small sample size compared with some previous studies. Medication
use was assessed at a single (initial) visit in which most patients were
Table 6. Patient Characteristics Associated With PIM Use (n  234)
Characteristic
No PIM
(n  115)
PIM
(n  119)
PNo. % No. %
Age, years .260
Mean 80.3 79.3
SD 7.2 6.3
Sex .534
Female 76 66 74 62
Male 39 34 45 38
Race/ethnicity .437
White 80 70 93 78
African American 24 21 21 18
Asian 6 5 3 3
Hispanic 4 3 2 2
Other 1 0.8 0
Functional status (n  232) .094
Fit 33 29 21 17
Frail 26 23 37 31
Vulnerable 55 48 60 51
PP  .001
None 30 26.09 7 5.88
PP 54 46.96 42 35.29
EPP 31 26.96 70 58.82
No. of comorbidities .005
Mean 7.26 8.66
SD 3.4 3.6
Median 7 8
Range 1-16 2-21
ECOG performance status (n  233) .361
0-1 87 76 83 70
2-4 28 24 35 30
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EPP, excessive
polypharmacy; PIM, potentially inappropriate medication; PP, polypharmacy;
SD, standard deviation.
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not receiving any anticancer treatments or cancer-related therapies.
Medication use in this population changes continuously, especially for
the patients who will begin anticancer and/or supportive care–related
therapies, so follow-up data on acceptance of pharmacist interven-
tions would strengthen study findings. Finally, patient outcomes asso-
ciated with excessive and inappropriate medication use—increased
use of health care resources (eg, hospitalizations) and adverse events
that compromised cancer management plans—were not captured.
A pharmacist-led comprehensive Older Adult Oncology med-
ication assessment demonstrated a high prevalence of PP, EPP, and
PIM use versus previously reported methodologies. The preva-
lence of PIMs varied depending on the screening tool applied, yet
the 2012 Beers criteria detected the highest prevalence of PIM use
in this population. Because of the minimal overlap between
2012 Beers and STOPP criteria, a modified PIM tool that inte-
grates 2012 Beers and STOPP criteria and considers cancer
diagnosis, prognosis, and cancer-related therapy is needed to
identify and minimize PIM use. Additional follow-up studies
are needed to longitudinally evaluate medication use to identify
associations with increased risk of adverse events that compro-
mise cancer management plans and worsen patient outcomes in
this complex and vulnerable population.
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Appendix
Table A1. Comorbidity Types Associated With PP Category (n  234)
Comorbidity
Type
No PP ( 5
medications)
(n  37)
Any PP ( 5
medications)
(n  197)
P
PP ( 5 and  10
medications)
(n  96)
EPP ( 10
medications)
(n  101)
PNo. % No. % No. % No. %
Cardiovascular 30 81.08 186 94.42 .012 86 89.6 100 99.0 .004
Endocrine 11 29.73 99 50.25 .030 41 42.7 58 57.4 .046
GI 8 21.62 97 49.24 .002 43 44.8 54 53.5 .255
Hematologic 9 24.32 69 35.03 .256 29 30.2 40 39.6 .181
Neurologic 6 16.22 77 36.09 .008 37 38.5 40 39.6 .885
Nutritional 7 18.92 29 14.72 .468 12 12.5 17 16.8 .427
Ophthalmologic 7 18.92 84 42.64 .006 35 36.5 49 48.5 .113
Psychiatric 12 32.43 76 38.58 .580 31 32.3 45 44.6 .081
Renal 3 8.11 40 20.30 .104 12 12.5 28 27.7 .008
Respiratory 5 13.51 79 40.10 .002 32 33.3 47 46.5 .081
Rheumatologic 21 56.76 125 63.45 .463 57 59.4 68 67.3 .300
Urologic 3 8.11 63 31.98 .002 26 27.1 37 36.6 .171
Abbreviations: EPP, excessive polypharmacy; PP, polypharmacy.
Table A2. Comorbidity Types Associated With PIM Use (n  234)
Comorbidity Type
No PIM (n  115) PIM (n  119)
PNo. % No. %
Cardiovascular 101 87.8 115 96.6 .014
Endocrine 57 49.6 53 44.5 .513
GI 42 36.5 63 52.9 .013
Hematologic 42 36.5 36 30.3 .334
Neurologic 32 27.8 51 42.9 .020
Nutritional 22 19.1 14 11.8 .147
Ophthalmologic 48 41.7 43 36.1 .422
Psychiatric 29 25.2 59 49.6  .001
Renal 22 19.1 21 17.7 .866
Respiratory 38 33.0 46 38.7 .414
Rheumatologic 72 62.6 74 62.2 1.000
Urologic 33 28.7 33 27.7 .886
Abbreviation: PIM, potentially inappropriate medication.
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Fig A1. Rate of potentially inappropriate medication (PIM) use between polypharmacy categories.
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